MENU
MAZE
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Maze Therapeutics (MAZE) Ownership - Who owns Maze Therapeutics?

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity... Show more

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
1.99B
P/E Ratio
191.34
Total Cash
383.94M
Projected Growth
N/A
Total Debt
24.18M
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
7.98
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

MAZE
Capitalization
1.99B
P/E Ratio
191.34
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
384M
Total Cash/Share
7.98
Total Debt
24.2M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
379M
P/B Ratio
5.25
Cash Flow
N/A
Earnings
-2.56
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
48K
Current Ratio
17.70
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-131.96M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-33.02
Shares Held By Institutions
1.14B
Shares Outstanding - Current
48.1M
Total Liabilities
42.6M
Total Volume MTD
N/A
Value
-1
Gain YTD
-0.097
View a ticker or compare two or three
MAZE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MAZE showed earnings on November 06, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details